Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

DARE

Dare Bioscience (DARE)

Dare Bioscience Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:DARE
일자시간출처헤드라인심볼기업
2024/05/1505:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAREDare Bioscience Inc
2024/05/1421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2024/05/1421:00GlobeNewswire Inc.Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
2024/05/1313:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DAREDare Bioscience Inc
2024/05/1105:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DAREDare Bioscience Inc
2024/05/0721:00GlobeNewswire Inc.Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024NASDAQ:DAREDare Bioscience Inc
2024/05/0221:00GlobeNewswire Inc.Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkNASDAQ:DAREDare Bioscience Inc
2024/04/3020:30GlobeNewswire Inc.Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsNASDAQ:DAREDare Bioscience Inc
2024/04/2321:00GlobeNewswire Inc.Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1NASDAQ:DAREDare Bioscience Inc
2024/04/1121:00GlobeNewswire Inc.Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
2024/03/2821:00GlobeNewswire Inc.Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
2024/03/2820:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:DAREDare Bioscience Inc
2024/03/2121:00GlobeNewswire Inc.Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024NASDAQ:DAREDare Bioscience Inc
2024/02/2222:00GlobeNewswire Inc.Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingNASDAQ:DAREDare Bioscience Inc
2024/01/3122:00GlobeNewswire Inc.Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024NASDAQ:DAREDare Bioscience Inc
2024/01/3006:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
2024/01/2707:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2024/01/2706:30GlobeNewswire Inc.Daré Bioscience Announces Executive Team and Board of Directors ChangesNASDAQ:DAREDare Bioscience Inc
2024/01/2006:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2024/01/1722:00GlobeNewswire Inc.Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentNASDAQ:DAREDare Bioscience Inc
2024/01/0822:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2024/01/0422:00GlobeNewswire Inc.Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesNASDAQ:DAREDare Bioscience Inc
2023/12/2706:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DAREDare Bioscience Inc
2023/12/2622:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2023/12/2622:00GlobeNewswire Inc.Daré Bioscience Secures $12 million in Royalty-backed Investment StructureNASDAQ:DAREDare Bioscience Inc
2023/12/2022:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
2023/12/2022:00GlobeNewswire Inc.Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical StudyNASDAQ:DAREDare Bioscience Inc
2023/12/1322:00GlobeNewswire Inc.Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical StudyNASDAQ:DAREDare Bioscience Inc
2023/12/0722:00GlobeNewswire Inc.Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with MenopauseNASDAQ:DAREDare Bioscience Inc
2023/12/0422:00GlobeNewswire Inc.Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
 검색 관련기사 보기:NASDAQ:DARE